ZMC(SH:600216) Xin Lang Cai Jing·2025-10-27 10:51Core Viewpoint - Zhejiang Medicine (600216.SH) announced that its subsidiary Changbei Biological plans to invest 1.685 billion yuan in the construction of the Zhejiang Medicine Changbei Biological Project, aimed at enhancing the self-sufficiency of raw materials for vitamins and reducing dependence on external key intermediates [1] Investment Details - The project will be constructed in two phases [1] - Upon completion, the project is expected to achieve an annual sales revenue of 900 million yuan and a gross profit of 286 million yuan [1] Strategic Rationale - The investment decision is based on the company's development strategy and business layout [1] - There is a noted uncertainty regarding the realization of future operational benefits from this investment [1]